Precision Medicine in Oncology®

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

The FDA has granted regular approval to rucaparib (Rubraca) for BRCA mutation–associated metastatic castration-resistant prostate cancer.

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

The FDA has approved niraparib and abiraterone acetate with prednisone for BRCA2-mutated mCSPC.

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

The FDA OKs the Oncomine Dx Target Test to identify patients with HER2 TKD–mutant NSCLC eligible for sevabertinib, enabling targeted treatment selection.

The FDA approved sevabertinib for previously treated, nonsquamous non–small cell lung cancer with HER2 TKD activating mutations.

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

GFH375 produced responses and tumor shrinkage in heavily pretreated pancreatic ductal adenocarcinoma harboring KRAS G12D mutations.

Here is your guide to all therapeutic options that were approved by the FDA in October 2025 spanning tumor types.

FDA grants fast track status to MT-125, a first-in-class NMII inhibitor, aiming to bring a novel treatment option to patients with aggressive glioblastoma.

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Switching to camizestrant plus a CDK4/6 inhibitor delayed symptom deterioration and improved QOL in HR+ breast cancer with the emergence of ESR1 mutations.

NorthStar findings support osimertinib plus local consolidative therapy in EGFR-mutant non–small cell lung cancer.

First-line alectinib produced a clinically meaningful overall survival benefit in advanced ALK-positive non–small cell lung cancer.